In August 2017, the NIH hosted a workshop to mark the 10th and final year of the Human Microbiome Project (HMP), a two-phase program that greatly increased our understanding of the role of human microbiota in human health and disease. Although this NIH initiative is over, it has spurred continued funding for human microbiome research from the NIH, other…Read more on Microbiome Modulation: The Next Frontier in Clinical Therapeutics
Fibromyalgia is a common medical condition characterized by chronic widespread muscle pain, fatigue, and sleep disturbance affecting two to three percent of the total population. It is five to ten times more common in women than men, increases with age and can also be worsened by many factors, including physical trauma and emotional stress. In…Read more on Why Treatment Advances in Fibromyalgia Have Been Slow
In this post, intended for a general audience, I share a few thoughts about the benefits and limitations of developing drugs using the 505(b)(2) regulatory pathway. Hardly a week goes by without a pharmaceutical company expressing the desire to reap the benefits of developing a drug using the “505(b)(2) regulatory pathway”. What are 505(b)(2) new drug…Read more on 505(b)(2) New Drug Applications: Is there an adequate ROI?
With 2017 upon us, many Alzheimer’s Disease (AD) stakeholders may look back at the year that was with a sense of dismay, given the failure of several important clinical trials aimed at translating putative mechanisms into FDA approved drugs. In this brief year-in-review, I say despair not. First, you could be suffering the January blues.…Read more on Alzheimer’s Disease Year-in-Review 2016
Published on December 29, 2016 by Dr. Najib Babul Neuropathic pain is pain arising as a direct consequence of a lesion or disease affecting the somatosensory system, or put more simply, pain due to injury to sensory nerves. Neuropathic pain can be broadly divided into peripheral neuropathic pain and central neuropathic pain. Until relatively recently,…Read more on Najib Babul – Opioids for Neuropathic Pain: Worth the Risk?